Tapentadol and Metabolite, Serum or Plasma, Quantitative
Ordering Recommendation
Monitor patient adherence.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Tue, Thu
1-6 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).  
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Unacceptable Conditions
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles.  
Submit With Order
Please indicate in the supplied fields:
1.  Dose - List drug amount and include the units of measure
2.  Route - List the route of administration (IV, oral, etc.)
3.  Dose Frequency - Indicate how often the dose is administered (per day, per week, as needed, etc.)
4.  Type of Draw - Indicate the type of blood draw (Peak, Trough, Random, etc.)  
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years  
Reference Interval
Effective August 17, 2015
Drugs Covered Cutoff Concentrations
Tapentadol 50 ng/mL
Tapentadol glucuronide 100 ng/mL
Tapentadol-​O-​sulfate (qualitative only) 100 ng/mL
N-​desmethyltapentadol (qualitative only) 100 ng/mL
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive Cutoff:
Tapentadol 50 ng/mL
Tapentadol glucuronide 100 ng/mL Tapentadol-O-sulfate 100 ng/mL
N-desmethyltapentadol 100 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is not uncommon and is consistent with recent use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
CPT Code(s)
80372; (Alt code: 80299)
Component Test Code*Component Chart NameLOINC
2003134Tapentadol, S/P, Quant59354-1
2003135N-desmethyltapentadol, S/P, Qual 
2005880Tapentadol glucuronide, S/P, Quant 
2005885Tapentadol-O-sulfate, S/P, Qual 
2011571Tapentadol Dose 
2011572Tapentadol Dose Frequency 
2011573Tapentadol Route 
2011574Tapentadol Type of Draw 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Nucynta
  • nucynta blood level
  • Tapentadol blood level